Hopkins' Stem Cell Selection Patents Upheld

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 8
Volume 6
Issue 8

WILMINGTON, Del--A Federal judge has ordered CellPro, Inc. to pay Johns Hopkins University, Becton Dickinson & Company, and Baxter Healthcare Corp. $7 million in damages for its willful infringement of patents involving stem cell selection technology.

WILMINGTON, Del--A Federal judge has ordered CellPro, Inc. to pay JohnsHopkins University, Becton Dickinson & Company, and Baxter HealthcareCorp. $7 million in damages for its willful infringement of patents involvingstem cell selection technology.

The judge also ordered an injunction against CellPro's patent-infringingstem cell selection system (Ceprate Stem Cell Concentration System andCeprate LC34 Laboratory Cell Separation System). This injunction will bedelayed in this country until an alternative system, licensed under thepatents, is approved by the FDA.

Johns Hopkins and its licensees requested the delay to ensure that transplantpatients have uninterrupted access to stem cell selection technology. Baxter'sIsolex 300 Magnetic Cell Separator System, already in widespread use inclinical trials, is currently under FDA review.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content